A multi-year study of the asthma drug Nucala (mepolizumab) has shown the treatment to be effective in asthma control and reducing acute episodes of the disease, according to GlaxoSmithKline Plc. The company disclosed the data on 20 May at a meeting of the American Thoracic Society.
